Q-omics provides the consensus-scored RNF222 profile across patient tissues and cancer cell-line models. RNF222 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, RNF222 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, RNF222 RNA expression shows 15,990 significant gene co-expression associations, with the highest sampling consensus in UVM. Together, these results highlight KIRC, HNSC, and UVM as cancer lineages where RNF222 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RNF222 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RNF222 survival associations across molecular data types. RNF222 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RNF222 RNA expression–survival associations across cancer types. High RNF222 expression shows unfavorable associations in KIRC, THCA, DLBC, UCEC and PCPG, but favorable associations in SCLC. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for RNF222 RNA expression.
This table summarizes RNF222 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for RNF222. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RNF222 shows lower tumor expression in HNSC and KICH and higher tumor expression in LUSC, LUAD, CHOL and COAD. The HNSC box plot shows higher RNF222 RNA expression in normal versus tumor tissue (log2 FC = −1.824, t-test p < 0.001).
This table shows molecular features associated with RNF222 in patient tissues and cancer cell lines. In patient samples, RNF222 shows the broadest associations at the RNA and protein expression levels, with UVM recurring as the lineage with the largest associated feature set. In cancer cell lines, RNF222 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LUNG_NSCLC_LUAD, while CRISPR and shRNA rows add functional-dependency signals in BLOOD_Leukemia.
